Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 30 of 58 results for durvalumab

  1. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development Reference number: GID-TA11504 Expected publication date:  04 February 2026

    Technology appraisal guidance
    In development

  2. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

    In development Reference number: GID-TA11405 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

    Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

    Technology appraisal guidance
    Published
    11 September 2024

    Sections for TA1005

  4. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development Reference number: GID-TA11232 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  5. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 February 2025

    Sections for TA1037

  6. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Technology appraisal and highly specialised technologies appeals

    Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.

  8. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development Reference number: GID-NG10404 Expected publication date: TBC

    NICE guideline
    In development

  9. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

    Technology appraisal guidance
    Published
    20 November 2024
    View recommendations

    Sections for TA1017

  10. Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]

    Discontinued Reference number: GID-TA10394

    Technology appraisal guidance
    Discontinued

  11. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued Reference number: GID-TA10324

    Technology appraisal guidance
    Discontinued

  12. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

    Technology appraisal guidance
    Discontinued

  13. Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

    Awaiting development Reference number: GID-TA11670 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued Reference number: GID-TA10633

    Technology appraisal guidance
    Discontinued

  15. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

    Discontinued Reference number: GID-TA10617

    Technology appraisal guidance
    Discontinued